Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

CSL312

Status:

Phase 2

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Intravenous (IV) Injection

Funder Type:

Industry

Drug Details

CSL312 (Garadacimab) is a humanised anti-FXIIa monoclonal antibody for the potential treatment of Interstitial Lung Diseases (ILD) and Idiopathic Pulmonary Fibrosis (IPF).

Study Purpose

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).

This drug has no clinical trials actively recruiting patients at this time.